Infecting human brain organoids with FFI or sCJD preserves prion traits regardless of host genotype

B R Groveman1,2, S T Foliaki1,2, K Williams1

  • 1Division of Intramural Research, Laboratory of Neurological Infections and Immunity, National Institute of Allergy and Infectious Diseases, Rocky Mountain Laboratories, National Institutes of Health, Hamilton, MT, USA.

NPJ Dementia
|October 6, 2025
PubMed

Insights

Sporadic Creutzfeldt-Jakob Disease (sCJD) and Fatal Familial Insomnia (FFI) prions can infect human brain organoids. The prion strain, not the organoid

Area of Science:

  • Neuroscience
  • Prion Biology
  • Molecular Genetics

Background:

  • Prion diseases are fatal neurodegenerative disorders.
  • These diseases stem from misfolded prion proteins (PrP).
  • Specific mutations, like D178N, cause genetic prion diseases such as Fatal Familial Insomnia (FFI).

Purpose of the Study:

  • To investigate the infectivity of sporadic Creutzfeldt-Jakob Disease (sCJD) and FFI prions in human cerebral organoids.
  • To determine if host genotype (D178N mutation) influences prion disease susceptibility in vitro.
  • To understand the fundamental mechanisms of prion propagation and host-pathogen interactions.

Main Methods:

  • Inoculation of human cerebral organoids with sCJD and FFI prions.
  • Culturing and monitoring of infected organoids.
  • Analysis of prion infection and propagation within the organoid model.

Main Results:

  • Both sCJD and FFI prions successfully infected human cerebral organoids.
  • Infection occurred regardless of the presence or absence of the D178N mutation in the organoid's PrP gene.
  • The genotype of the host organoid did not dictate the susceptibility or outcome of prion infection.

Conclusions:

  • Human cerebral organoids serve as a viable model for studying prion diseases.
  • Prion infectivity is determined by the prion strain itself, not the host's genetic background.
  • This finding has implications for understanding prion disease pathogenesis and developing therapeutic strategies.